Canaccord raised the firm’s price target on Taysha Gene Therapies (TSHA) to $9 from $8 and keeps a Buy rating on the shares. The firm updated it model following Q1 results where the key takeaway was a “best case scenario” regulatory update for TSHA-102. The co has reached alignment + received written confirmation from the FDA on key elements of the pivotal Part B trial design in line with what the company had initially been targeting.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies: Promising FDA Alignment and Strong Financials Justify Buy Rating
- Taysha Gene Therapies Advances in Rett Syndrome Trials
- Taysha Gene Therapies’ Positive Q1 2025 Earnings Call
- Positive Outlook for Taysha Gene Therapies: Expedited FDA Alignment and Strong Financial Position Support Buy Rating
- Taysha Gene Therapies reports Q1 EPS (8c) vs (10c) last year
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue